An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for non-small cell lung cancer (Version 2.2021). National Comprehensive Cancer Network, Inc.
   Google Scholar
• Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr;387(10026):1415–1426.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nature reviews clinical oncology. Nov 01 2018;Vol. 15(11)Nature Publishing Group. 694–708.
   Google Scholar
• Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011 Apr;17(8):2081–2086.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-Line Crizotinib versus chemotherapy in ALK -positive lung cancer. N Engl J Med. 2014 Dec;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2017 Aug;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2018 Nov;379(21):2027–2039.
   PubMed Web of Science ®Google Scholar
• Selvaggi G, Wakelee HA, Mok T, et al. ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3. J Thorac Oncol. 2020 Oct;15(10):e41–e42.
   Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Sci Transl Med. 2012 Feb;4(120). 10.1126/scitranslmed.3003316.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer. Clin Cancer Res. 2012 Mar;18(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer. Cancer Discov. 2016 Oct;6(10):1118–1133. study is the largest retrospective work studying the molecular mechanisms to different generation ALK-TKIs
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015 Mar;112(11):3493–3498.
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack D, et al. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul;28(1):70–81.
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations. J Med Chem. 2014 Jun;57(11):4720–4744.
   PubMed Web of Science ®Google Scholar
• “Pfizer Inc. LORBRENA (lorlatinib): prescribing information.” 2021. [Online]. Available: http://labeling.pfizer.com/ShowLabeling.aspx?id=11140.
   Google Scholar
• Chen J, O’Gorman MT, James LP, et al. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: results from a Global Phase I/II Study. Clin Pharmacokinet. 2021 Oct;60(10):1313–1324.
   PubMed Web of Science ®Google Scholar
• Stypinski D, Fostvedt L, Lam JL, et al. Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF‐06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies. J Clin Pharmacol. 2020 Sep;60(9):1254–1267.
   PubMed Web of Science ®Google Scholar
• Schinkel AH. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev. 1999 Apr;36(2–3):179–194.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017 Dec;18(12):1590–1599. phase I trial evaluated the safety, tolerability, efficacy and pharmacokinetics of lorlatinib in advanced ALK-positive NSCLC who had been previously treated with ALK-TKIs
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK -Positive Non–Small-Cell Lung Cancer: results From PROFILE 1014. JCO. 2016 Aug;34(24):2858–2865.
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 Mar;389(10072):917–929.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018 Dec;19(12):1654–1667.
   PubMed Web of Science ®Google Scholar
• Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021 May;32(5):620–630.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Besse B, et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. J Clin Oncol. 2019 Jun;37(16):1370–1379.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Martinin JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). JCO. 2019 May;37(15_suppl):9019.
   Web of Science ®Google Scholar
• Frost N, Christopoulos P, Kauffmann-Guerrero D, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 2021 Jan;13:175883592098055.
   Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer. N Engl J Med. 2020 Nov;383(21):2018–2029. phase III study explored lorlatinib as a first-line treatment in patients with ALK-positive advanced NSCLC
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Mok T, et al. Abstract CT223: updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Cancer Res. 2022 Jun;82(12_Supplement):CT223–CT223.
   Google Scholar
• Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients With ALK -positive advanced non–small-cell lung cancer from the Phase III CROWN Study. JCO. 2022 May JCO.21.02278. 10.1200/JCO.21.02278
   Google Scholar
• Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019 Jul;14(7):1233–1243.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov;29(11):2214–2222.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020;38(31):3592–3603.
   PubMed Web of Science ®Google Scholar
• Camidge D, Kim HR, Ahn M-J, et al. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021 Dec;16(12):2091–2108.
   PubMed Web of Science ®Google Scholar
• Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 Jun;8(6):714–729.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Lin JJ, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res. 2019 Nov;25(22):6662–6670.
   PubMed Web of Science ®Google Scholar
• Shiba-Ishii A, Johnson TW, Dagogo-Jack I, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer. 2022 Jun;3(6):710–722.
   PubMedGoogle Scholar
• Cui JJ, Rogers E, Zhai D, et al. Abstract 5226: TPX-0131: a next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors. Cancer Res. 2020 Aug;80(16_Supplement):5226.
   Web of Science ®Google Scholar
• Murray BW, Zhai D, Deng W, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021 Sep;20(9):1499–1507.
   PubMed Web of Science ®Google Scholar
• Pelish HE, Tangpeerachaikul A, Kohl NE, et al. Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation. Cancer Res. 2021 Jul;81(13_Supplement):1468.
   Web of Science ®Google Scholar
• Tangpeerachaikul A, Bigot L, Friboulet L, et al. Abstract 3337: preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer. Cancer Res. 2022 Jun;82(12_Supplement):3337.
   Google Scholar
• Felip E, Martini J, Mazieres J, et al. “1008P - Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC),” presented at the ESMO Congress 2022, Paris, 2022 Sep 10.
   Google Scholar
• Recondo G, Mezquita L, Facchinetti F, et al. Diverse resistance mechanisms to the third-generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clin Cancer Res. 2020 Jan;26(1):242–255.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019 Aug;24(8):1103–1110.
   PubMed Web of Science ®Google Scholar
• Reed M, Rosales ALS, Chioda MD, et al. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Adv Ther. 2020 Jun;37(6):3019–3030.
   PubMed Web of Science ®Google Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 Aug;31(8):1056–1064.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Kim DW, Wu Y-L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer. JCO. 2018 Aug;36(22):2251–2258.
   PubMed Web of Science ®Google Scholar
• Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK -positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017 Mar;8(13):21903–21917.
   PubMedGoogle Scholar
• Baldacci S, Besse B, Avrillon V, et al. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022 May;166:51–59.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Brannon AR, Ferris LA, et al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis Oncol. 2018 Nov;2018(2):1–14.
   Google Scholar
• Mezquita L, Swalduz A, Jovelet C, et al. Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 Fusion and resistance mutations in patients with non–small-cell lung cancer. JCO Precis Oncol. 2020 Sep;4(4):272–282.
   Google Scholar